Investigational Site Number : 6820001
Riyadh, Saudi Arabia
2 recruiting
Showing 1–4 of 4 trials
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
Dermatitis Atopic
Sanofi390 enrolled146 locationsNCT06241118
Recruiting
Phase 3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Multiple Sclerosis
Sanofi1,600 enrolled384 locationsNCT06141473
Recruiting
Phase 3
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
Sanofi124 enrolled66 locationsNCT07190196
Recruiting
Phase 3
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Multiple Sclerosis
Sanofi900 enrolled338 locationsNCT06141486